1. Home
  2. GGR vs ACET Comparison

GGR vs ACET Comparison

Compare GGR & ACET Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Gogoro Inc.

GGR

Gogoro Inc.

HOLD

Current Price

$2.96

Market Cap

83.3M

ML Signal

HOLD

Logo Adicet Bio Inc.

ACET

Adicet Bio Inc.

HOLD

Current Price

$4.52

Market Cap

83.3M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
GGR
ACET
Founded
2011
1947
Country
Taiwan
United States
Employees
N/A
N/A
Industry
Auto Manufacturing
Biotechnology: Pharmaceutical Preparations
Sector
Consumer Discretionary
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
83.3M
83.3M
IPO Year
2021
2017

Fundamental Metrics

Financial Performance
Metric
GGR
ACET
Price
$2.96
$4.52
Analyst Decision
Strong Buy
Analyst Count
0
6
Target Price
N/A
★ $34.83
AVG Volume (30 Days)
12.9K
★ 297.5K
Earning Date
11-10-2026
11-04-2026
Dividend Yield
N/A
N/A
EPS Growth
★ N/A
N/A
EPS
★ N/A
N/A
Revenue
N/A
N/A
Revenue This Year
$4.97
N/A
Revenue Next Year
$6.11
N/A
P/E Ratio
N/A
★ N/A
Revenue Growth
N/A
N/A
52 Week Low
$2.02
$0.46
52 Week High
$5.43
$9.97

Technical Indicators

Market Signals
Indicator
GGR
ACET
Relative Strength Index (RSI) 53.13 25.78
Support Level $2.85 N/A
Resistance Level $3.33 $8.54
Average True Range (ATR) 0.17 0.45
MACD -0.00 -0.15
Stochastic Oscillator 58.49 4.50

Price Performance

Historical Comparison
GGR
ACET

About GGR Gogoro Inc.

Gogoro Inc is focused on eliminating the barriers to electric fuel adoption to bring swappable electric power within reach of every urban rider. Its battery swapping technology compromises an interoperable platform that seamlessly integrates a comprehensive ecosystem of hardware, software, and services, which consists of Gogoro Smart Batteries, GoStations, Gogoro Network Software & Battery Management Systems, Smartscooter, and related components and kits. Geographical presence in Taiwan and Other countries, majority of its revenue comes from Tiwan.

About ACET Adicet Bio Inc.

Adicet Bio Inc is a clinical-stage biotechnology company discovering and developing allogeneic gamma delta T cell therapies for autoimmune diseases and cancer. It is advancing a pipeline of off-the-shelf gamma delta T cells, engineered with chimeric antigen receptors (CARs), to facilitate durable activity in patients. The company's main product candidate, prulacabtagene leucel (prula-cel), is an allogeneic gamma delta T cell therapy expressing a CAR targeting CD20, and is being developed for the potential treatment of autoimmune diseases. Additionally, it is pursuing ADI-212, a next-generation gene-edited and armored clinical candidate designed to target prostate-specific membrane antigen (PSMA).

Share on Social Networks: